3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
11
Phase 1/2
8
Phase 1
6
Phase 3
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
95
Carcinoma, Non-Small-Cell Lung
87
Lung Neoplasms
21
Squamous Cell Carcinoma of Head and Neck
19
Melanoma
19
Triple Negative Breast Neoplasms
14
Stomach Neoplasms
13
Breast Neoplasms
13
Neoplasm Metastasis
11
Head and Neck Neoplasms
11
Carcinoma, Renal Cell
11
Endometrial Neoplasms
10
Urinary Bladder Neoplasms
9
Neoplasms
9
Carcinoma
9
Carcinoma, Transitional Cell
7
Carcinoma, Hepatocellular
7
Colorectal Neoplasms
6
Uterine Cervical Neoplasms
4
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Neoplasms by Site
4
Esophageal Neoplasms
4
Cholangiocarcinoma
4
Thoracic Neoplasms
3
Small Cell Lung Carcinoma
3
Skin Neoplasms
3
Respiratory Tract Neoplasms
3
Respiratory Tract Diseases
3
Lung Diseases
3
Interventions
Dexamethasone
169
Bortezomib
92
Lenalidomide
85
daratumumab
44
Thalidomide
44
pomalidomide
43
Melphalan
40
Cyclophosphamide
33
carfilzomib
29
Calcium Dobesilate
27
Prednisone
19
Doxorubicin
16
elotuzumab
14
isatuximab
12
Filgrastim
12
ixazomib
11
Vincristine
10
Peripheral Blood Stem Cell Transplantation
10
belantamab mafodotin
9
Granulocyte Colony-Stimulating Factor
9
Zoledronic Acid
8
selinexor
7
dexamethasone acetate
7
Epoetin Alfa
7
Etoposide
6
fludarabine
5
Cisplatin
5
Carmustine
5
iberdomide
4
Radiotherapy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Multiple Myeloma
×
pembrolizumab
×
Clear all
NCT02576977
2021-10-08
KEYNOTE 183
Merck Sharp & Dohme LLC
Phase 3
Terminated
251 enrolled
17 charts
NCT02579863
2021-07-20
KEYNOTE 185
Merck Sharp & Dohme LLC
Phase 3
Terminated
310 enrolled
16 charts